Showing results (341-350 of 367) with videos related to

Sort By:
Pageof 37
Therapeutic Advances in Medical Oncology|November 7, 2022
Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study GroupHye Sook Han, Kyoung Eun Lee, Young Ju Suh, et al.
The Lancet. Oncology|February 20, 2025
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 studyHee Kyung Ahn, Ji-Yeon Kim, Kyung-Hun Lee, et al.
Breast Cancer Research and Treatment|December 19, 2023
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCYJudith Balmaña, Peter A Fasching, Fergus J Couch, et al.
The Lancet Regional Health. Western Pacific|July 21, 2025
Prevalence of germline BRCA1/2 pathogenic variants in unselected Korean patients with HER2-negative metastatic breast cancer: a nationwide prospective study (KCSG BR19-10)Hee Kyung Ahn, Jee Hung Kim, Su-Jin Koh, et al.
BMC Medicine|March 17, 2022
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysisRyan Shea Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, et al.
Breast (Edinburgh, Scotland)|August 27, 2022
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, et al.
Lancet (London, England)|April 22, 2023
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trialFabrice André, Yeon Hee Park, Sung-Bae Kim, et al.
The New England Journal of Medicine|February 9, 2022
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Rebecca Dent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT TrialPeter Schmid, Jacinta Abraham, Stephen Chan, et al.
Breast (Edinburgh, Scotland)|November 3, 2019
Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16-12)Jae Sik Kim, Kyubo Kim, Wonguen Jung, et al.
Pageof 37